Axogen Raises Full Year Revenue Guidance After Strong Q3 Beat

Axogen reported third quarter 2026 revenue of $75.8 million, a 26.2% increase from $60.1 million in the same period a year earlier, and raised its full year revenue guidance to at least 29% growth, equating to $290 million. The results were filed with the SEC via a Form 8-K on October 28, 2026, which also included an updated corporate presentation posted to the company's investor relations website.

Net income for the quarter was $2.3 million, or $0.04 per share, up from $0.7 million, or $0.01 per share, in Q3 2025. Adjusted net income more than doubled to $13.1 million, or $0.21 per share, compared to $6.1 million, or $0.12 per share, a year ago. Gross margin came in at 74.8%, slightly below the 76.6% recorded in the prior year period.

Revenue growth was described as broad-based across Axogen's Extremities, Oral Maxillofacial and Head and Neck, and Breast segments, driven by more than 20% year-over-year account productivity gains, an expanding sales force, and improving commercial insurance coverage. The company noted that commercial payer coverage for its Avance nerve graft product reached approximately 96% of covered lives in the United States following positive coverage decisions from Elevance and Aetna. Options implied volatility for AXGN also rose on the day of the release, reflecting heightened market attention around the earnings event.